CN102988419A - Toad skin extract powder inhalant, and preparation method and application thereof - Google Patents
Toad skin extract powder inhalant, and preparation method and application thereof Download PDFInfo
- Publication number
- CN102988419A CN102988419A CN2012105579327A CN201210557932A CN102988419A CN 102988419 A CN102988419 A CN 102988419A CN 2012105579327 A CN2012105579327 A CN 2012105579327A CN 201210557932 A CN201210557932 A CN 201210557932A CN 102988419 A CN102988419 A CN 102988419A
- Authority
- CN
- China
- Prior art keywords
- cutis bufonis
- preparation
- extract
- bufonis extract
- inhalant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 117
- 239000000843 powder Substances 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title abstract description 57
- 239000003814 drug Substances 0.000 claims abstract description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 250
- 239000000203 mixture Substances 0.000 claims description 37
- OBRNDARFFFHCGE-QDSVTUBZSA-N arformoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-QDSVTUBZSA-N 0.000 claims description 36
- 239000000796 flavoring agent Substances 0.000 claims description 33
- 235000019634 flavors Nutrition 0.000 claims description 33
- 229940079593 drug Drugs 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000002775 capsule Substances 0.000 claims description 25
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 23
- 239000008101 lactose Substances 0.000 claims description 23
- 239000006228 supernatant Substances 0.000 claims description 19
- 229960000193 formoterol fumarate Drugs 0.000 claims description 18
- 239000002671 adjuvant Substances 0.000 claims description 14
- 238000012869 ethanol precipitation Methods 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 8
- 206010013786 Dry skin Diseases 0.000 claims description 3
- 238000002347 injection Methods 0.000 abstract description 36
- 239000007924 injection Substances 0.000 abstract description 36
- 230000000694 effects Effects 0.000 abstract description 16
- 208000020816 lung neoplasm Diseases 0.000 abstract description 7
- 208000037841 lung tumor Diseases 0.000 abstract description 6
- 238000010579 first pass effect Methods 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract 2
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 229960004756 ethanol Drugs 0.000 description 61
- 238000001694 spray drying Methods 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 230000002685 pulmonary effect Effects 0.000 description 16
- 239000008187 granular material Substances 0.000 description 15
- 210000004072 lung Anatomy 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 9
- 230000008021 deposition Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 238000010298 pulverizing process Methods 0.000 description 8
- -1 reflux Substances 0.000 description 7
- XFIMEMVNMWDPRW-UHFFFAOYSA-O C1=C(OS(O)=O)C([N+](C)(C)CC2)=C3C2=CNC3=C1 Chemical compound C1=C(OS(O)=O)C([N+](C)(C)CC2)=C3C2=CNC3=C1 XFIMEMVNMWDPRW-UHFFFAOYSA-O 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000005325 percolation Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 238000000703 high-speed centrifugation Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000005374 membrane filtration Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241001415440 Bufo gargarizans Species 0.000 description 3
- 241000269420 Bufonidae Species 0.000 description 3
- VOZHMAYHYHEWBW-NVOOAVKYSA-N Bufotalin Chemical class C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@H]5CC[C@H]4[C@@]3(O)C[C@@H]2OC(=O)C)C=CC(=O)OC=1 VOZHMAYHYHEWBW-NVOOAVKYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 240000002853 Nelumbo nucifera Species 0.000 description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 206010003671 Atrioventricular Block Diseases 0.000 description 2
- 241000269417 Bufo Species 0.000 description 2
- VOZHMAYHYHEWBW-UHFFFAOYSA-N Bufotalin Natural products CC(=O)OC1CC2(O)C3CCC4CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 VOZHMAYHYHEWBW-UHFFFAOYSA-N 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000007888 Sinus Tachycardia Diseases 0.000 description 2
- 206010040741 Sinus bradycardia Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- HDTHCLKLBSPBIS-JBXNKDOXSA-N (2s)-2-[[8-[[(3s,5r,8r,9s,10s,13r,14s,16s,17r)-16-acetyloxy-14-hydroxy-10,13-dimethyl-17-(6-oxopyran-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-8-oxooctanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical group C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@@H](C[C@H]5CC[C@H]4[C@@]3(O)C[C@@H]2OC(=O)C)OC(=O)CCCCCCC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C=CC(=O)OC=1 HDTHCLKLBSPBIS-JBXNKDOXSA-N 0.000 description 1
- RYDFXSRVZBYYJV-TYYBGVCCSA-N (e)-but-2-enedioic acid;sodium Chemical compound [Na].OC(=O)\C=C\C(O)=O RYDFXSRVZBYYJV-TYYBGVCCSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 1
- 229930190011 Bufogenin Natural products 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- SCULJPGYOQQXTK-OLRINKBESA-N Cinobufagin Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@H]5CC[C@H]4[C@@]43O[C@@H]4[C@@H]2OC(=O)C)C=CC(=O)OC=1 SCULJPGYOQQXTK-OLRINKBESA-N 0.000 description 1
- SCULJPGYOQQXTK-UHFFFAOYSA-N Cinobufagin Natural products CC(=O)OC1C2OC22C3CCC4CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 SCULJPGYOQQXTK-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 241001415432 Duttaphrynus melanostictus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- ATLJNLYIJOCWJE-CWMZOUAVSA-N bufogenin Chemical compound C=1([C@H]2C[C@H]3O[C@@]43[C@H]3[C@@H]([C@]5(CC[C@H](O)C[C@H]5CC3)C)CC[C@@]42C)C=CC(=O)OC=1 ATLJNLYIJOCWJE-CWMZOUAVSA-N 0.000 description 1
- 229950006858 bufogenin Drugs 0.000 description 1
- VTTONGPRPXSUTJ-UHFFFAOYSA-N bufotenin Chemical class C1=C(O)C=C2C(CCN(C)C)=CNC2=C1 VTTONGPRPXSUTJ-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930005303 indole alkaloid Natural products 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a powder inhalant, in particular to a powder inhalant made of toad skin extract, a preparation method of the powder inhalant, and the application of the powder inhalant in the preparation of a medicine for treating lung tumor. The toad skin extract powder inhalant is characterized by comprising the toad skin extract and a medically acceptable auxiliary material, wherein the mass ratio between the toad skin extract and the auxiliary material is 1: 0-1: 110. The powder inhalant made of the toad skin extract is directly used for treating lung diseases, reduces the toxic and side effects, improves the bioavailability of the medicine, and overcomes the defects that the oral preparation is slow in effect, has hepatic first-pass effect and whole body toxic and side effects, is lower in preparation bioavailability and the like; and furthermore, the toad skin extract powder inhalant solves the problems the injection is inconvenient to use, poor in patient compliance, etc.
Description
Technical field:
The present invention relates to Foradil Aerolizer formoterol fumarate, specifically the preparation method of the Foradil Aerolizer formoterol fumarate made of Cutis Bufonis extract, described Foradil Aerolizer formoterol fumarate and the application in preparation treatment lung tumors medicine.
Background technology:
Cinobufacin is the extract that the dry skin of Bufonidae (Bufonidae) animal Bufo siccus Bufobufo gargarizans Cantor makes through extracting purification, effect with detoxifcation, detumescence, pain relieving, in being used for the treatment of, the disease such as late tumor, chronic hepatitis B, its biological active substances mainly is bufotoxin class (bufotoxins) and hydrolyzate bufotalin class (bufageins), bufotenine class (bufoteinines) etc.Present cinobufacin injection, oral liquid, tablet have been applied to clinical, and hepatocarcinoma, pulmonary carcinoma, gastric cancer etc. are had preferably curative effect.Especially HUACHANSU ZHUSHEYE, from the water soluble preparation of Skin of Bufo bufo gargarizans through being processed into, treatment primary hepatocarcinoma and medium and advanced lung cancer obtain respectively 44% and 56% comprehensive effective percentage, and tumor body minification is respectively 10% and 16%, and chemotherapy and radiation is had synergism.Although the clinical untoward reaction of HUACHANSU ZHUSHEYE is less, but still exist the intravenous drip meeting local vein reaction to occur, cause that the instillation vein shrinks spasm and causes pain, long-time stimulus causes the vein nonspecific inflammation; Dermoreaction, main manifestations are urticaria and the infringement of skin blister sample; Secondly, the cardiovascular system reactions such as premature beat, sinus bradycardia, sinus tachycardia, atrioventricular block appear in small part patient, and the possible cause of generation is the cardiotoxicity that bufotalin a small amount of in the cinobufacin produces.In addition, injection need to use in hospital, and patient compliance is poor.And the cinobufacin oral formulations need be through the first pass effect of liver, and onset is slow, and the preparation bioavailability is lower.
Lung has great surface area, and alveolar wall is comprised of cell monolayer, so that drug molecule very easily enters blood, so the lung inhalation has the plurality of advantages such as rapid-action, that untoward reaction is little.(the drypowder inhalers of Foradil Aerolizer formoterol fumarate in the lung inhalation, DPIs) do not use propellant and solvent, the air-flow that produces by patient's autonomous respiration makes the drug powder atomizing, and then make drug powder be delivered to pulmonary, have use convenient, absorb rapidly, without liver firstly cross, the characteristics of rapid release and targeting location, be a kind of novel drug-supplying system.
The sickness rate of pulmonary carcinoma rises rapidly in worldwide, has become first of the cancer cause of the death.Current antitumor drug great majority all are drug administration by injection, and this whole body administering mode is unfavorable for drug accumulation in tumor locus, cause the curative effect of medicine to reduce, and untoward reaction increases.
Adopt site-specific delivery of drugs that antitumor drug is transported to the tumor patient part of human body, medicine is improved in the concentration of patient part, the toxic and side effects that reduces medicine, the therapeutic effect that improves medicine are had great clinical value.Employing can directly be transmitted Cutis Bufonis extract the focus of pulmonary carcinoma through the inhalant of lung administering mode, is conducive to improve Cutis Bufonis extract to the curative effect of pulmonary carcinoma and reduces the toxic and side effects of its normal tissue.The research that has at present the Cutis Bufonis extract Foradil Aerolizer formoterol fumarate of resisting tumor of lung effect has no report.
Summary of the invention:
Goal of the invention: an object of the present invention is to provide pulmonary's dry powder inhaler formulations of Cutis Bufonis extract and preparation method thereof.Another object of the present invention provides the application of Foradil Aerolizer formoterol fumarate of the present invention in preparation treatment lung tumors medicine.
For the foregoing invention purpose, the invention provides following technical scheme:
A kind of Cutis Bufonis extract Foradil Aerolizer formoterol fumarate is characterized in that it is comprised of Cutis Bufonis extract and medically acceptable adjuvant, and Cutis Bufonis extract (according to gained solids quality after the drying) is 1:0-1:110 with the mass ratio of described adjuvant.
Described a kind of Cutis Bufonis extract Foradil Aerolizer formoterol fumarate is to add the powder that adjuvant is made by Cutis Bufonis extract, and powder agglomeration forms re-dispersable particles; Or Cutis Bufonis extract loads on granules of accessories surface formation granule; The particle diameter of above-mentioned two kinds of granules is with D
50Meter is between the 0.5-1000 micron.
Described Cutis Bufonis extract, the extract that makes through extracting purification for the skins of Bufonidae animal Bufo siccus or Bufo melanostictus etc.The preparation method of Cutis Bufonis extract is:
Get 1 part of Cutis Bufonis, add 2-100 times of water gaging, backflow or decoction or ultrasonic or microwave or lixiviate or percolation extract 1-10 time, 0.1-48 hour at every turn, merge water extraction liquid, being concentrated into relative density is 1.01-1.50(60-100 ℃), add ethanol (65%-100%, W/W) precipitation, make ethanol content reach 50%(W/W) more than, leave standstill or centrifugal or filtration treatment, get the supernatant Recycled ethanol, obtain obtaining Cutis Bufonis extract after Cutis Bufonis extract or concentrated, the drying.
Perhaps, get 1 part of Cutis Bufonis, add 2-100 times of water gaging, backflow or decoction or ultrasonic or microwave or lixiviate or percolation extract 1-10 time, and each 0.1-48 hour, merging water extraction liquid, being concentrated into relative density is 1.01-1.50(60-100 ℃), add ethanol (65%-100%, W/W) precipitation, make ethanol content reach 50%(W/W) more than, leave standstill or centrifugal or filtration treatment, get the supernatant Recycled ethanol to without the alcohol flavor, add ethanol (65%-100%, W/W) precipitation, make ethanol content reach 60%(W/W) more than, leave standstill or centrifugal or filtration treatment, get the supernatant Recycled ethanol to without the alcohol flavor, obtain Cutis Bufonis extract or concentrated, obtain Cutis Bufonis extract after the drying.
Perhaps, get 1 part of Cutis Bufonis, add 2-100 times of water gaging, backflow or decoction or ultrasonic or microwave or lixiviate or percolation extract 1-10 time, each 0.1-48 hour, merge water extraction liquid, through the ultrafilter membrane ultrafiltration of molecular weight 500-5000, obtain obtaining Cutis Bufonis extract after Cutis Bufonis extract or concentrated, the drying.
Perhaps, get 1 part of Cutis Bufonis, add the certain density ethanol (1%-100%, W/W) that 2-100 doubly measures, reflux or ultrasonic or microwave or lixiviate or percolation extract 1-10 time, each 0.1-48 hour, merge extractive liquid,, Recycled ethanol adds 0-100 times of water to without the alcohol flavor, leave standstill or centrifugal or filtration treatment, obtain obtaining Cutis Bufonis extract after Cutis Bufonis extract or concentrated, the drying.
Perhaps, get 1 part of Cutis Bufonis, add the certain density ethanol (1%-100%, W/W) that 2-100 doubly measures, reflux or ultrasonic or microwave or lixiviate or percolation extract 1-10 time, each 0.1-48 hour, merge extractive liquid,, Recycled ethanol adds 0-100 times of water to without the alcohol flavor, through the ultrafilter membrane ultrafiltration of molecular weight 500-5000, obtain obtaining Cutis Bufonis extract after Cutis Bufonis extract or concentrated, the drying.
Described adjuvant is selected one or more mixture in sugar, alcohol, aminoacid, phospholipid, surfactant, cyclodextrin, polymer substance, magnesium stearate, stearic acid, hard ester fumaric acid sodium, micropowder silica gel, the Pulvis Talci.
Described sugar can be selected one or more mixture in galactose, lactose, glucose, fructose, sucrose, trehalose, the Raffinose; Described alcohol can be selected one or more mixture in mannitol, xylitol, maltose alcohol, the sorbitol; Described aminoacid can be selected one or more in glycine, Aspartic Acid, alanine, tryptophan, isoleucine, threonine, glutamic acid, phenylalanine, leucine, cystine, lysine, proline, the arginine; Described phospholipid can be selected one or more in soybean phospholipid, lecithin, phosphatidylcholine, PHOSPHATIDYL ETHANOLAMINE, the synthetic phospholipid; Described surfactant can be selected one or more mixture in pulmonary surfactant such as dipalmitoyl phosphatidyl choline, DLPC, the cholesterol; Described polymer substance, can select the macromolecule that meets safety requirements, preferred biodegradable polymer substance is one or more mixture in albumin, starch, polylactic acid, poly lactic-co-glycolic acid, Polyethylene Glycol, poloxamer, hyaluronic acid, hyaluronate sodium, the sodium alginate for example.
Preferred mode is described adjuvant for sucking with the lactose granule mean diameter at 45-220 micron and the micronization lactose mean diameter mixture at the 1-10 micron, and wherein the mass ratio of lactose granule and micronization lactose is 1000:1-1:1.Most preferred mode is that the mass ratio of lactose granule and micronization lactose is 100:1-7:1.
A kind of method for preparing the Cutis Bufonis extract Foradil Aerolizer formoterol fumarate, its preparation process is as follows:
Cutis Bufonis extract is made powder by pulverizing or spray drying, be packaged in capsule or bubble-cap or the Diskus; Cutis Bufonis extract is made powder by pulverizing or spray drying, and powder and adjuvant mix homogeneously are made to suck and are used powder, are packaged in capsule or bubble-cap or the Diskus; Perhaps with Cutis Bufonis extract and adjuvant mix homogeneously, make suction by pulverizing or spray drying and use powder, be packaged in capsule or bubble-cap or the Diskus; Perhaps with partial supplementary material mix homogeneously in Cutis Bufonis extract and the prescription, make powder by pulverizing or spray drying, residue adjuvant mix homogeneously is made to suck and is used powder in powder and the prescription, is packaged in capsule or bubble-cap or the Diskus.
A kind of method for preparing the Cutis Bufonis extract Foradil Aerolizer formoterol fumarate, its preparation process is as follows:
Cutis Bufonis extract is made powder by pulverizing or spray drying, powder and adjuvant mix homogeneously, reuniting forms re-dispersable particles, is packaged in capsule or bubble-cap or the Diskus; Perhaps with Cutis Bufonis extract and adjuvant mix homogeneously, make powder by pulverizing or spray drying, reuniting forms re-dispersable particles, is packaged in capsule or bubble-cap or the Diskus; Perhaps with partial supplementary material mix homogeneously in Cutis Bufonis extract and the prescription, make powder by pulverizing or spray drying, residue adjuvant mix homogeneously in powder and the prescription, the formation re-dispersable particles of reuniting is packaged in capsule or bubble-cap or the Diskus; Perhaps Cutis Bufonis extract is made powder by pulverizing or spray drying, powder load forms granule on the granules of accessories surface, is packaged in capsule or bubble-cap or the Diskus.
The application of a kind of Cutis Bufonis extract Foradil Aerolizer formoterol fumarate in preparation lung tumors medicine.
Beneficial effect:
1, lung has great surface area, and alveolar wall is comprised of cell monolayer, so that drug molecule very easily enters blood, so the lung inhalation has the plurality of advantages such as rapid-action, that untoward reaction is little.(the drypowder inhalers of Foradil Aerolizer formoterol fumarate in the lung inhalation, DPIs) do not use propellant and solvent, the air-flow that produces by patient's autonomous respiration makes the drug powder atomizing, and then make drug powder be delivered to pulmonary, have use convenient, absorb rapidly, without liver firstly cross, the characteristics of rapid release and targeting location, be a kind of novel drug-supplying system.At present multiplex in the infection for the treatment of respiratory tract and pulmonary relevant for Foradil Aerolizer formoterol fumarate, but have no treatment at lung tumors.Simultaneously, the research that has a Cutis Bufonis extract Foradil Aerolizer formoterol fumarate of resisting tumor of lung effect also has no report.Present Cutis Bufonis extract injection, oral liquid, tablet have been applied to clinical, and hepatocarcinoma, pulmonary carcinoma, gastric cancer etc. are had preferably effect.Especially HUACHANSU ZHUSHEYE, from the water soluble preparation of Skin of Bufo bufo gargarizans through being processed into, treatment primary hepatocarcinoma and medium and advanced lung cancer obtain respectively 44% and 56% comprehensive effective percentage, and tumor body minification is respectively 10% and 16%, and chemotherapy and radiation is had synergism.Although the clinical untoward reaction of HUACHANSU ZHUSHEYE is less, but still exist the intravenous drip meeting local vein reaction to occur, cause that the instillation vein shrinks spasm and causes pain, long-time stimulus causes the vein nonspecific inflammation; Dermoreaction, main manifestations are urticaria and the infringement of skin blister sample; Secondly, the cardiovascular system reactions such as premature beat, sinus bradycardia, sinus tachycardia, atrioventricular block appear in small part patient, and the possible cause of generation is the cardiotoxicity that bufotalin a small amount of in the cinobufacin produces.Injection need to use in hospital in addition, and patient compliance is poor.And the Cutis Bufonis extract oral formulations need be through the first pass effect of liver, and onset is slow, and the preparation bioavailability is lower.Using the Foradil Aerolizer formoterol fumarate of Cutis Bufonis extract mainly is for lung tumors, directly acts on affected part, does not have the first pass effect of liver simultaneously, rapid-action, and does not have above-mentioned untoward reaction, and new drug development is had great prospect.
2, because Cutis Bufonis extract is mixture, wherein contain indole alkaloids, cinobufagin, bufogenin etc., in practical operation, find, when the specific adjuvant that adds certain proportioning can overcome extract and is crushed to certain particle diameter and the reunion that the electrostatic interaction that produces, cohesiveness etc. cause reduces hygroscopicity.The applicant knows that through great many of experiments particularly adjuvant is selected the mixture of lactose granule and micronization lactose or adopted the powder agglomeration technology can make the good Foradil Aerolizer formoterol fumarate of intake performance.
The specific embodiment
Below in conjunction with example the present invention is described in further detail, but scope of the present invention is not subjected to any restriction of these examples.
Embodiment 1
1, the preparation of Cutis Bufonis extract: get dry maxima skin and clean, add 10 times of water gagings, decoct 2 times, each 1.5 hours, merging filtrate, being concentrated into relative density is 1.1-1.2 (85 ℃), be cooled to 40 ℃, add ethanol precipitation, make to contain the alcohol amount and reach 60%, left standstill 24 hours, and got the supernatant Recycled ethanol to without alcohol flavor, concentrated solution adds ethanol to be made and contains the alcohol amount and reach 85%, left standstill 48 hours, and filtered, Recycled ethanol is to thick paste, 60 ℃ of dryings obtain Cutis Bufonis extract.
2, the preparation of inhalant: adopt comminution by gas stream to D Cutis Bufonis extract
50Below 5 microns, with particle diameter the lactose of 45-70 micron in mass ratio 1:10 mix, drug powder is packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 2
1, the preparation of Cutis Bufonis extract: get dry maxima skin and clean, add 12 times of water gagings, decoct 2 times, each 2 hours, merging filtrate, being concentrated into relative density is 1.2-1.3 (85 ℃), be cooled to 40 ℃, add ethanol precipitation, make to contain the alcohol amount and reach 70%, left standstill 24 hours, and got the supernatant Recycled ethanol to without alcohol flavor, concentrated solution adds ethanol to be made and contains the alcohol amount and reach 85%, left standstill 48 hours, and filtered, Recycled ethanol is to distinguishing the flavor of without alcohol, spray drying obtains the Cutis Bufonis extract powder, powder D
50Below 5 microns.
2, the preparation of inhalant: with Cutis Bufonis extract powder, particle diameter the lactose of 45-80 micron, particle diameter the leucine of 20-50 micron in mass ratio the ratio of 10:100:1 mix, be packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 3
1, the preparation of Cutis Bufonis extract: get dry maxima skin and clean, add 30 times of water gagings, microwave-assisted extracts 3 times, and each 1 hour, merge extractive liquid,, through the ultrafilter membrane ultrafiltration of molecular weight 1000, the ultrafiltrate spray drying obtains the Cutis Bufonis extract powder, powder D
50Below 5 microns.
2, the preparation of inhalant: the Cutis Bufonis extract powder packets is packed in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 4
1, the ethanol preparation of Cutis Bufonis extract: get Cutis Bufonis and clean, add 12 times of amount 60%(W/W), reflux, extract, 2 times, each 2 hours, merge extractive liquid,, Recycled ethanol is to distinguish the flavor of deepfreeze 48 hours without alcohol, filter, the active carbon (W/V) of adding 0.3% boiled 30 minutes, filtered, spray drying obtains the Cutis Bufonis extract powder.
2, the preparation of inhalant: with Cutis Bufonis extract powder, lactose, mannitol, glycine, DLPC, lecithin, magnesium stearate in mass ratio the ratio of 1:5:5:2:0.5:0.5:0.1 mix, comminution by gas stream is to powder D
50Below 5 microns, drug powder is packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 5
1, the preparation of Cutis Bufonis extract: get Cutis Bufonis and clean, the dehydrated alcohol that adds 20 times of amounts, reflux, extract, 2 times, each 1 hour, merge extractive liquid,, Recycled ethanol, ultrafilter membrane ultrafiltration through molecular weight 3000, ultrafiltrate vacuum concentration to proportion is 1.20 (45 ℃), and 50 ℃ of vacuum dryings of extractum obtain Cutis Bufonis extract.
2, the preparation of inhalant: Cutis Bufonis extract, lactose, cholesterol are mixed in the ratio of 1:8:1, and comminution by gas stream is to powder D
50Below 5 microns, drug powder is packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 6
1, the preparation of Cutis Bufonis extract: get Cutis Bufonis and clean, add the 60%(W/W of 15 times of amounts) ethanol, reflux, extract, 3 times, each 1 hour, merge extractive liquid,, Recycled ethanol is to distinguishing the flavor of without alcohol, and it is heavy that concentrated solution adds 2 times of water gagings, left standstill 24 hours, high speed centrifugation is got supernatant and is obtained Cutis Bufonis extract.
2, the preparation of inhalant: lactose, polyethylene glycol 6000, the albumin with 5 times, 1 times, 2 times of contained solid qualities in the above-mentioned Cutis Bufonis extract adds in the Cutis Bufonis extract spray drying, powder D respectively
50Below 5 microns, drug powder is packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 7
1, the preparation of Cutis Bufonis extract: get Cutis Bufonis and clean, add the 10%(W/W of 10 times of amounts) ethanol, reflux, extract, 2 times, each 1 hour, merge extractive liquid,, Recycled ethanol is to distinguishing the flavor of without alcohol, and the concentrated solution high speed centrifugation is got supernatant and is obtained Cutis Bufonis extract, spray drying obtains Cutis Bufonis extract, powder D
50Below 5 microns.
2, the preparation of inhalant: with Cutis Bufonis extract drug powder, particle diameter the mannitol of 10-90 micron, micronization silica gel in mass ratio the ratio of 10:89:1 mix, be packaged into behind the mix homogeneously in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 8
1, the preparation of Cutis Bufonis extract: get Cutis Bufonis and clean, add the 50%(W/W of 10 times of amounts) ethanol, reflux, extract, 2 times, each 1 hour, merge extractive liquid,, Recycled ethanol is to distinguish the flavor of the concentrated solution high speed centrifugation without alcohol, get supernatant and obtain Cutis Bufonis extract, spray drying obtains the Cutis Bufonis extract powder.
2, the preparation of inhalant: with Cutis Bufonis extract drug powder, mannitol, leucine in mass ratio the ratio of 10:100:3 mix, it is an amount of to add water after the mixing, spray drying obtains D
50Be 4.8 microns powder, mix with the rotary blender that polymer inner liner is arranged, make loose aggregate, the D of aggregate
50Be 390 microns, be packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 9
1, the preparation of Cutis Bufonis extract: get Cutis Bufonis and clean, add the 40%(W/W of 10 times of amounts) ethanol, reflux, extract, 3 times, each 0.5 hour, merge extractive liquid,, Recycled ethanol is to distinguish the flavor of the concentrated solution high speed centrifugation without alcohol, get supernatant and obtain Cutis Bufonis extract, spray drying, powder D
50Below 5 microns.
2, the preparation of inhalant: with Cutis Bufonis extract powder, mannitol, leucine in mass ratio the ratio of 10:80:2 mix, mix with the rotary blender that polymer inner liner is arranged, make loose aggregate, the D of aggregate
50Be 120 microns, be packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 10
1, the preparation of Cutis Bufonis extract: get dry maxima skin and clean, add 20 times of water gagings, decoct 2 times, each 2 hours, merging filtrate, being concentrated into relative density is 1.2-1.3 (85 ℃), be cooled to 40 ℃, add ethanol precipitation, make to contain the alcohol amount and reach 70%, left standstill 24 hours, and got the supernatant Recycled ethanol to without alcohol flavor, concentrated solution adds ethanol to be made and contains the alcohol amount and reach 85%, left standstill 48 hours, and filtered, Recycled ethanol is to distinguishing the flavor of without alcohol, spray drying, powder D
50Below 5 microns.
2, the preparation of inhalant: with Cutis Bufonis extract powder, happy InhaLac 70 lactose of German U.S. agent, micronization lactose (D
50=5.1 microns) in mass ratio the ratio of 5:90:5 mix, be packaged into behind the mix homogeneously in capsule or bubble-cap or the Diskus, obtain inhalant.
3, the inhalant pulmonary deposition ratio is investigated
Investigate according to People's Republic of China's version pharmacopeia in 2010 prescriptive procedure, with bufothionine content meter in the preparation, its pulmonary deposition ratio reaches 32.6%, places after 18 months under the room temperature condition, and the pulmonary deposition ratio of bufothionine does not have significant change in the preparation.
Embodiment 11
1, the preparation of Cutis Bufonis extract: get dry maxima skin and clean, add 20 times of water gagings, decoct 2 times, each 2 hours, merging filtrate, being concentrated into relative density is 1.2-1.3 (85 ℃), be cooled to 40 ℃, add ethanol precipitation, make to contain the alcohol amount and reach 70%, left standstill 24 hours, and got the supernatant Recycled ethanol to without alcohol flavor, concentrated solution adds ethanol to be made and contains the alcohol amount and reach 85%, left standstill 48 hours, and filtered, Recycled ethanol is to distinguishing the flavor of without alcohol, spray drying, powder D
50Below 5 microns.
2, the preparation of inhalant: with Cutis Bufonis extract powder, happy InhaLac 70 lactose of German U.S. agent, micronization lactose (D
50=4.9 microns) in mass ratio the ratio of 3:95:1 mix, be packaged into behind the mix homogeneously in capsule or bubble-cap or the Diskus, obtain inhalant.
3, the inhalant pulmonary deposition ratio is investigated
Investigate according to People's Republic of China's version pharmacopeia in 2010 prescriptive procedure, with bufothionine content meter in the preparation, its pulmonary deposition ratio reaches 30.2%, places after 18 months under the room temperature condition, and the pulmonary deposition ratio of bufothionine does not have significant change in the preparation.
Embodiment 12
1, the preparation of Cutis Bufonis extract: get dry maxima skin and clean, add 20 times of water gagings, decoct 2 times, each 2 hours, merging filtrate, being concentrated into relative density is 1.2-1.3 (85 ℃), be cooled to 40 ℃, add ethanol precipitation, make to contain the alcohol amount and reach 70%, left standstill 24 hours, and got the supernatant Recycled ethanol to without alcohol flavor, concentrated solution adds ethanol to be made and contains the alcohol amount and reach 85%, left standstill 48 hours, and filtered, Recycled ethanol is to distinguishing the flavor of without alcohol, spray drying, powder D
50Below 5 microns.
2, the preparation of inhalant: with Cutis Bufonis extract powder, happy InhaLac 70 lactose of German U.S. agent, micronization lactose (D
50=5.5 microns) in mass ratio the ratio of 3:77:11 mix, be packaged into behind the mix homogeneously in capsule or bubble-cap or the Diskus, obtain inhalant.
3, the inhalant pulmonary deposition ratio is investigated
Investigate according to People's Republic of China's version pharmacopeia in 2010 prescriptive procedure, with bufothionine content meter in the preparation, its pulmonary deposition ratio reaches 29.8%, places after 18 months under the room temperature condition, and the pulmonary deposition ratio of bufothionine does not have significant change in the preparation.
Embodiment 13
1, the preparation of Cutis Bufonis extract: get dry maxima skin and clean, add 10 times of water gagings, decoct 2 times, each 1 hour, merging filtrate, being concentrated into relative density is 1.3-1.4 (85 ℃), be cooled to 40 ℃, add ethanol precipitation, make to contain the alcohol amount and reach 60%, left standstill 48 hours, and got the supernatant Recycled ethanol to without alcohol flavor, concentrated solution adds ethanol to be made and contains the alcohol amount and reach 80%, left standstill 48 hours, and filtered, Recycled ethanol is to distinguishing the flavor of without alcohol, spray drying, powder D
50Below 5 microns.
2, the preparation of inhalant: Cutis Bufonis extract powder, leucine are mixed the D of granule after mixing in the ratio of 1:5
50Be 292 microns, be packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 14
1, the preparation of Cutis Bufonis extract: get dry maxima skin and clean, add 6 times of water gagings, decoct 5 times, each 1 hour, merging filtrate, being concentrated into relative density is 1.05 (70 ℃), be cooled to 40 ℃, add ethanol precipitation, make to contain the alcohol amount and reach 65%, left standstill 48 hours, and got the supernatant Recycled ethanol to without alcohol flavor, concentrated solution adds ethanol to be made and contains the alcohol amount and reach 70%, left standstill 48 hours, and filtered, Recycled ethanol is to distinguishing the flavor of without alcohol, concentrating under reduced pressure, vacuum drying obtains Cutis Bufonis extract.
2, the preparation of inhalant: Cutis Bufonis extract is mixed comminution by gas stream, powder D with leucine in the ratio of 1:1
50Below 5 microns, this powder is mixed again the D of granule after mixing with the mannitol of 9 times of amounts
50Be 328 microns, be packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 15
1, the preparation of Cutis Bufonis extract: get dry maxima skin and clean, add 30 times of water gagings, decocted 1 hour, it is 1.30 (60 ℃) that extracting solution is concentrated into relative density, is cooled to 20 ℃, adds the ethanol precipitation, make to contain alcohol amount and reach 70%, left standstill 24 hours, get the supernatant Recycled ethanol to without the alcohol flavor, concentrated solution adds ethanol to be made and contains alcohol amount and reach 90%, left standstill 48 hours, and filtered, Recycled ethanol is to distinguishing the flavor of without alcohol, concentrating under reduced pressure, vacuum drying obtains Cutis Bufonis extract.
2, the preparation of inhalant: with Cutis Bufonis extract and poloxamer in mass ratio the ratio of 10:1 mix comminution by gas stream, powder D
50Below 5 microns, this powder is mixed again the D of granule after mixing with the lactose granule of 8 times of amounts, the magnesium stearate of 1 times of amount
50Be 653 microns, be packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 16
1, the preparation of Cutis Bufonis extract: get Cutis Bufonis and clean, add 10 times of water gagings, decocted 1 hour, it is 1.20 (50 ℃) that extracting solution is concentrated into relative density, is cooled to room temperature, adds the ethanol precipitation, make to contain alcohol amount and reach 50%, left standstill 24 hours, get the supernatant Recycled ethanol to without the alcohol flavor, concentrated solution adds ethanol to be made and contains alcohol amount and reach 70%, left standstill 48 hours, and filtered, Recycled ethanol is to distinguishing the flavor of without alcohol, concentrating under reduced pressure, vacuum drying obtains Cutis Bufonis extract.
2, the preparation of inhalant: with the Cutis Bufonis extract comminution by gas stream, powder D
50Below 5 microns, this powder is mixed again the D of granule after mixing with the lactose granule of 20 times of amounts
50Be 286 microns, be packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 17
Obtain inhalant according to embodiment 1-16, carry out pharmacodynamic experiment, wherein drugs compared is HUACHANSU ZHUSHEYE (commercially available), Cutis Bufonis injection A and B, and Cutis Bufonis injection A and B prepare in accordance with the following methods:
Cutis Bufonis injection A:
Get dry maxima skin and clean, add 15 times of water gagings, decoct each 2 hours 2 times, merging filtrate, being concentrated into relative density is 1.2 (85 ℃), is cooled to 20 ℃, adds the ethanol precipitation, make to contain alcohol amount and reach 60%, left standstill 24 hours, get the supernatant Recycled ethanol to without the alcohol flavor, concentrated solution adds ethanol to be made and contains alcohol amount and reach 85%, leaves standstill 48 hours, filters, Recycled ethanol adds water to every milliliter and is equivalent to crude drug in whole 5g to without the alcohol flavor, regulates pH to 6.5,0.45 the micron membrane filtration, embedding, pressure sterilizing and get final product.
Cutis Bufonis injection B:
Get dry maxima skin and clean, add 20 times of amount 60% ethanol, reflux, extract, 2 times, each 2 hours, merge extractive liquid,, Recycled ethanol is to distinguishing the flavor of without alcohol, add 3 times of water gagings, deepfreeze 48 hours filters, the active carbon (W/V) of adding 0.3% boiled 30 minutes, filtered, add water to every milliliter and be equivalent to crude drug in whole 5g, regulate pH to 7,0.45 micron membrane filtration, embedding, pressure sterilizing and get final product.
Effect experiment:
The method of benzopyrene percutaneous puncture pulmonary injection is set up the induced lung animal model for tumour, gets 200 of modeling rats, is divided at random 20 groups, 10 every group.Every day 1 time, medication 7 days.Administering mode: 1-16 group is that the inhalant inhalation of embodiment 1-16, dosage are 15g crude drug/kg; The 17th group of lumbar injection HUACHANSU ZHUSHEYE (commercially available), dosage: 15g crude drug/kg; The 18th group of lumbar injection Cutis Bufonis injection A, dosage: 15g crude drug/kg; The 19th group of lumbar injection Cutis Bufonis injection B, dosage: 15g crude drug/kg; The 20th group is physiology saline control group, lumbar injection 10mL/kg.Next day is put to death rat in drug withdrawal, dissects lungs, observes the lung lesion situation.
Experimental result: it is 10.5% that the pulmonary of rat of each group of inhalant administration the incidence rate of lump or nodular lesion occurs minimum, is up to 30.3%; HUACHANSU ZHUSHEYE group (commercially available) is 60.5%, Cutis Bufonis injection A group is 50.1%, Cutis Bufonis injection B group is 60.8%, the normal saline group is 100%, and each group of inhalant administration has significant difference (P＜0.05) with HUACHANSU ZHUSHEYE group (commercially available), Cutis Bufonis injection A group, Cutis Bufonis injection B group, normal saline group in the pulmonary lesion incidence rate.
Embodiment 18
Obtain inhalant according to embodiment 1-16, carry out pharmacodynamic experiment, wherein drugs compared is HUACHANSU ZHUSHEYE (commercially available), Cutis Bufonis injection A and B, and Cutis Bufonis injection A and B prepare in accordance with the following methods:
Cutis Bufonis injection A:
Get dry maxima skin and clean, add 15 times of water gagings, decoct each 2 hours 2 times, merging filtrate, being concentrated into relative density is 1.2 (85 ℃), is cooled to 20 ℃, adds the ethanol precipitation, make to contain alcohol amount and reach 60%, left standstill 24 hours, get the supernatant Recycled ethanol to without the alcohol flavor, concentrated solution adds ethanol to be made and contains alcohol amount and reach 85%, leaves standstill 48 hours, filters, Recycled ethanol adds water to every milliliter and is equivalent to crude drug in whole 5g to without the alcohol flavor, regulates pH to 6.5,0.45 the micron membrane filtration, embedding, pressure sterilizing and get final product.
Cutis Bufonis injection B:
Get dry maxima skin and clean, add 20 times of amount 60% ethanol, reflux, extract, 2 times, each 2 hours, merge extractive liquid,, Recycled ethanol is to distinguishing the flavor of without alcohol, add 3 times of water gagings, deepfreeze 48 hours filters, the active carbon (W/V) of adding 0.3% boiled 30 minutes, filtered, add water to every milliliter and be equivalent to crude drug in whole 5g, regulate pH to 7,0.45 micron membrane filtration, embedding, pressure sterilizing and get final product.
Effect experiment:
1, the foundation of rabbit VX2 original position lung cancer model
1) the freezing cell suspension of the conventional recovery VX2 tumor of the making of lotus tumor kind rabbit makes 10
6The living cells suspension of/mL is got 1mL and is inoculated in 1 rabbit right rear leg outside intramuscular, can lay one's hand on and the lump of a diameter 30cm in inoculation position after 3 weeks, namely makes lotus tumor kind rabbit.
2) cut the intramuscular tumor in the lotus tumor kind rabbit leg outside under the preparation aseptic condition of piece of tissue suspension, get to be and oppress the eugonic tumor tissues of sample, be cut into the mud shape.30 mesh sieves were descended in the flushing of RPMI 1640 culture fluid, removed individual cells and too small piece of tissue, and part was descended 20 mesh sieves in the flushing of RPMI RPMI-1640 on the sieve, removed excessive piece of tissue.Get the lower part of screen and divide, after the centrifugation, taking precipitate 2mL adds the RPMI RPMI-1640 and is mixed with piece of tissue suspension 20mL.
3) all rabbit right thoracic wall depilations of inoculation in the lung, intramuscular injection speed is slept and is fixed after new mixture 0.8mL/kg anaesthetizes, routine disinfection, get aseptic three way cock, connecing respectively No. 12 injection needles, suctions has the 1mL syringe of rabbit self blood clot and the syringe that suction has VX2 tumor tissue suspension or cell suspension 1mL.Under X-ray examination, No. 12 syringe needles are thrust in the rabbit inferior lobe of right lung, behind the resorption depletion of blood, inject 0.4mL piece of tissue suspension or cell suspension, then inject 0.2mL rabbit self blood clot, extract syringe needle, inoculate complete.
4) the whole rabbit of the observation of growth of xenografted situation were from after the inoculation the 3rd day, and carry out layer wide, bed thickness be 5mm CT scan to chest every day, observed transfer case in tumor growth, the thoracic cavity.
5) rabbit VX2 original position lung cancer model is set up as a result rabbit all tumor growth in the lung, success ratio of inoculation 100%.
2, effect experiment:
Get successfully 200 of modeling rabbit, be divided at random 20 groups, 10 every group.Every day 1 time, medication 12 days.Administering mode: 1-16 group is the inhalant inhalation of embodiment 1-16, dosage: 15g crude drug/kg; The 17th group of lumbar injection HUACHANSU ZHUSHEYE (commercially available), dosage: 15g crude drug/kg; The 18th group of lumbar injection Cutis Bufonis injection A, dosage: 15g crude drug/kg; The 19th group of lumbar injection Cutis Bufonis injection B, dosage: 15g crude drug/kg; The 20th group is physiology saline control group, lumbar injection 10mL/kg.Next day is put to death rabbit in drug withdrawal, dissects the rabbit lungs, peels off tumor tissues, weighs.
Experimental result: the tumour inhibiting rate minimum of the rabbit of each group of inhalant administration is 58.7%, is up to 64.3%; HUACHANSU ZHUSHEYE group (commercially available) is 56.3%, Cutis Bufonis injection A group is 45.1%, Cutis Bufonis injection B group is 48.9%, normal saline is to almost unrestraint effect of tumor, and each group of inhalant administration has significant difference (P＜0.05) with the tumour inhibiting rate of HUACHANSU ZHUSHEYE group (commercially available), Cutis Bufonis injection A group, Cutis Bufonis injection B group, normal saline group.
Claims (1)
1. Cutis Bufonis extract Foradil Aerolizer formoterol fumarate is characterized in that it is comprised of Cutis Bufonis extract and medically acceptable adjuvant;
Being prepared as of described Cutis Bufonis extract: get dry maxima skin and clean, add 10 times of water gagings, decoct 2 times, each 1.5 hours, merging filtrate, being concentrated into 85 ℃ of lower relative densities is 1.1-1.2, be cooled to 40 ℃, add ethanol precipitation, make to contain the alcohol amount and reach 60%, left standstill 24 hours, and got the supernatant Recycled ethanol to without alcohol flavor, concentrated solution adds ethanol to be made and contains the alcohol amount and reach 85%, left standstill 48 hours, and filtered, Recycled ethanol is to thick paste, 60 ℃ of dryings obtain Cutis Bufonis extract;
Being prepared as of described inhalant: adopt comminution by gas stream to D Cutis Bufonis extract
50Below 5 microns, with particle diameter the lactose of 45-70 micron in mass ratio 1:10 mix, drug powder is packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105579327A CN102988419A (en) | 2011-06-02 | 2011-06-02 | Toad skin extract powder inhalant, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105579327A CN102988419A (en) | 2011-06-02 | 2011-06-02 | Toad skin extract powder inhalant, and preparation method and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101478093A Division CN102210712B (en) | 2011-06-02 | 2011-06-02 | A kind of toad skin extract dry powder inhalation agent and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102988419A true CN102988419A (en) | 2013-03-27 |
Family
ID=47917844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012105579327A Pending CN102988419A (en) | 2011-06-02 | 2011-06-02 | Toad skin extract powder inhalant, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102988419A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104055797A (en) * | 2014-06-17 | 2014-09-24 | 安徽华润金蟾药业股份有限公司 | Detection and identification of two composition components in toad skin extract |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1686183A (en) * | 2005-03-25 | 2005-10-26 | 张海峰 | Toad cake freeze dried powder injection agent and its preparation method |
| CN1813802A (en) * | 2005-02-04 | 2006-08-09 | 安徽金蟾生化股份有限公司 | Production process of cinobufacin (toad skin) extract |
-
2011
- 2011-06-02 CN CN2012105579327A patent/CN102988419A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813802A (en) * | 2005-02-04 | 2006-08-09 | 安徽金蟾生化股份有限公司 | Production process of cinobufacin (toad skin) extract |
| CN1686183A (en) * | 2005-03-25 | 2005-10-26 | 张海峰 | Toad cake freeze dried powder injection agent and its preparation method |
Non-Patent Citations (3)
| Title |
|---|
| 史宁，吴久鸿: "干粉吸入剂的研究进展", 《中国新药杂志》 * |
| 晁耀烁等: "华蟾素雾化吸入治疗慢性阻塞性肺病的初步研究", 《中华实用中西医杂志》 * |
| 缪旭等: "影响干粉吸入剂雾化和沉积性能的制剂因素", 《国际药学研究杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104055797A (en) * | 2014-06-17 | 2014-09-24 | 安徽华润金蟾药业股份有限公司 | Detection and identification of two composition components in toad skin extract |
| CN104055797B (en) * | 2014-06-17 | 2016-02-03 | 安徽华润金蟾药业股份有限公司 | The detection and identification of two based composition compositions in toad skin extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101239081A (en) | A composition for treating cancer and its preparation method | |
| CN102058566A (en) | Dry powder inhaler with constituent rubescensin A as well as preparation method and application thereof | |
| CN102961409B (en) | Toad skin extract dry powder inhaler | |
| CN102247335B (en) | Bufalin dry powder inhalant as well as preparation method and application thereof | |
| CN102961406B (en) | Toad skin extract dry powder inhaler, as well as preparation method and application thereof | |
| CN102302477B (en) | Cinobufagin dry power inhaler and preparation method and application thereof | |
| CN102210712A (en) | A kind of toad skin extract dry powder inhalation agent and its preparation method and application | |
| CN102302475B (en) | Resibufogenin dry powder inhalant and preparation method and application thereof | |
| CN103083286B (en) | Toad venom lipophilic extract dry powder inhaler, as well as preparation method and application thereof | |
| CN102210711B (en) | A dry powder inhaler of toad venom fat-soluble extract and its preparation method and application | |
| CN103070885B (en) | Toad skin extract dry-powder inhalant and its preparation method and use | |
| CN103070886B (en) | Toad skin extract dry-powder inhalant and its preparation method and use | |
| CN102961408B (en) | Toad skin extract dry powder inhaler | |
| CN102973605B (en) | Toad skin extract dry powder inhalant and preparation method and applications thereof | |
| CN102973604B (en) | Toad skin extract dry powder inhalant and preparation method and applications thereof | |
| CN102247336B (en) | Bufothionine dry powder inhaler, and its preparation method and application | |
| CN106913858A (en) | Eucheuma polypeptide prevents and treats the application of pulmonary fibrosis | |
| CN102247337B (en) | Bufotalin dry powder inhalers and preparation method as well as application thereof | |
| CN103142652B (en) | Venenum bufonis fat-soluble extract dry powder inhaler, and preparation method and application thereof | |
| CN101623286B (en) | Transdermal administration composite containing cucurbitacin-type active ingredient | |
| CN102961407B (en) | Toad skin extract dry powder inhaler, as well as preparation method and application thereof | |
| CN102302476B (en) | Dehydrobufotenine dry power inhaler and preparation method and application thereof | |
| CN101396373A (en) | Cinobufacini extract and preparation method thereof | |
| CN115737691A (en) | Ganoderma lucidum strong-effect component and preparation method thereof | |
| CN102988422A (en) | American cockroach nano extract and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130327 |